ArticleClinical journal of the American Society of Nephrology : CJASN2019
Risk of ESKD in Older Live Kidney Donors with Hypertension.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- Effectiveness of a Mobile Health System on Compliance With 2-Year Living Kidney Donor Follow-Up in the United States.Clinical transplantation · 2025Trial
- Genetic Evaluation Practices in Living Kidney Donor Candidates.Kidney international reports · 2026Article
- Long-term kidney outcomes after living donation in older adults: clinical findings and equation-dependent eGFR estimates.BMC geriatrics · 2026Article
- Evaluation and Counseling of Living Kidney Donor Candidates.Journal of the American Society of Nephrology : JASN · 2026Review
- Hypertension after living kidney donation: incidence, predictors, and consequences.BMC nephrology · 2025Article
- Renal outcome of living kidney donors aged more than 70 years.Clinical and experimental nephrology · 2024Article
- Living kidney donors with HIV: experience and outcomes from a case series by the HOPE in Action Consortium.Lancet regional health. Americas · 2023Article
- Telemedicine services for living kidney donation: A US survey of multidisciplinary providers.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- Intermediate Renal Outcomes, Kidney Failure, and Mortality in Obese Kidney Donors.Journal of the American Society of Nephrology : JASN · 2021Article
- The Scope of Telemedicine in Kidney Transplantation: Access and Outreach Services.Advances in chronic kidney disease · 2021Review
- Hypertension and obesity in living kidney donors.World journal of transplantation · 2021Review
- Renal function outcomes and kidney biopsy features of living kidney donors with hypertension.Clinical transplantation · 2021Article
- Outcomes of Hypertensive Kidney Donors Using Current and Past Hypertension Definitions.Kidney international reports · 2021Article
- The first increase in live kidney donation in the United States in 15 years.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020Article
- Blood Pressure and Living Kidney Donors: A Clinical Perspective.Transplantation direct · 2019Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesHypertension in older kidney donor candidates is viewed as safe. However, hypertension guidelines have evolved and long-term outcomes have not been explored. We sought to quantify the 15-year risk of ESKD and mortality in older donors (≥50 years old) with versus those without hypertension. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A United States cohort of 24,533 older donors from 1999 to 2016, including 2265 with predonation hypertension, were linked to Centers for Medicare and Medicaid Services data and the Social Security Death Master File to ascertain ESKD development and mortality. The exposure of interest was predonation hypertension. From 2004 to 2016, hypertension was defined as documented predonation use of antihypertensive therapy, regardless of systolic BP or diastolic BP; from 1999 to 2003, when there was no documentation of antihypertensive therapy, hypertension was defined as predonation systolic BP ≥140 or diastolic BP ≥90 mm Hg.
resultsOlder donors were 82% white, 6% black, 7% Hispanic, and 3% Asian. The median follow-up was 7.1 years (interquartile range, 3.4-11.1; maximum, 18). There were 24 ESKD and 252 death events during the study period. The 15-year risk of ESKD was 0.8% (95% confidence interval [95% CI], 0.4 to 1.6) for donors with hypertension (mean systolic BP, 138 mm Hg) versus 0.2% (95% CI, 0.1 to 0.4) for donors without hypertension (mean systolic BP, 123 mm Hg; adjusted hazard ratio, 3.04; 95% CI, 1.28 to 7.22;
conclusionsCompared with older donors without hypertension, older donors with hypertension had higher risk of ESKD, but not mortality, for 15 years postdonation. However, the absolute risk of ESKD was small.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.